Exscientia is pleased to announce the appointment of Andy Bell as Head of Chemistry. Andy is one of the world’s leading medicinal chemists as a co-inventor of sildenafil and as a contributor to the development of voriconazole. These medicines have generated sales of nearly $40 billion.
Andy first worked on PDE inhibitors leading to the inotrope/vasodilator (PDE3) candidate, nanterinone, and the PDE5 inhibitor, sildenafil (Viagra, Revatio). After the discovery of sildenafil in 1989, Andy shifted focus to antifungals, where he contributed to the candidate nomination voriconazole (Vfend) a broad-spectrum agent launched in 2002.
Andy also had responsibilities for file enrichment, as part of Pfizer’s collaborations with ArQule and Tripos. He has worked in the hit-to-lead arena, to generate new lead series for multiple projects, including novel series of selective PDE inhibitors; NaV1.7 channel blockers; H4 and Alpha 2a antagonists. A strong collaborator, Andy worked with colleagues to create library design tools, develop HTS triage methods.
Since leaving Pfizer in 2011, Andy has been at Imperial College, London, leading the medicinal chemistry effort on a project to discover novel inhibitors of N-myristoyltransferase for the treatment of parasitic infections.
Andy was awarded the Technical Achievement Award in Organic Chemistry by the American Chemical Society in recognition for his considerable contributions to medicinal chemistry.
The appointment of Andy is recognition of ex scientia’s continued ability to recruit world-class innovators to its operations.